Nautilus Biotechnology (NAUT) Consolidated Net Income (2020 - 2021)
Nautilus Biotechnology's (NAUT) quarterly Consolidated Net Income came in at -$1.8 million in Q1 2021, down 209.01% quarter-over-quarter from -$576035.0 in Q4 2020.
Nautilus Biotechnology (NAUT) Consolidated Net Income (2020 - 2021) Analysis & Trends
Nautilus Biotechnology has disclosed Consolidated Net Income across 2 years of filings, most recently posting -$1.8 million for Q1 2021.
- Consolidated Net Income for Q1 2021 came in at -$1.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was -$1.8 million (changed N/A YoY), and the FY2020 annual result was -$576035.0, changed N/A from the prior year.
- Consolidated Net Income came in at -$1.8 million for Q1 2021 at Nautilus Biotechnology, down from -$576035.0 in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$174671.0 in Q3 2020 to a low of -$1.8 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Nautilus Biotechnology | 298.22 Mn | 202.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | -1.78 Mn |
| Dec 31, 2020 | -576,035.00 |
| Sep 30, 2020 | -174,671.00 |